TY - JOUR
T1 - Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold
AU - Jin, Xin
AU - Merrett, James
AU - Tong, Sheng
AU - Flower, Bartholomew
AU - Xie, Jianling
AU - Yu, Rilei
AU - Tian, Shuye
AU - Gao, Ling
AU - Zhao, Jiajun
AU - Wang, Xuemin
AU - Jiang, Tao
AU - Proud, Christopher G.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - The mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate eukaryotic initiation factor 4E (eIF4E) and play important roles in promoting tumorigenesis and metabolic disease. Thus, inhibiting these enzymes might be valuable in the treatment of such conditions. We designed and synthesized a series of 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine derivatives, and evaluated their inhibitory activity against the MNKs. We found 15 compounds that were active as MNK inhibitors and that one in particular, designated MNK-7g, which was potent against MNK1 and substantially more potent against MNK2. The compound MNK-7g did not affect other signaling pathways tested and had no adverse effects on cell viability. As expected from earlier studies, MNK-7g also inhibited cell migration. Therefore, the compound MNK-7g, which forms an ionic bond with Asp226 in MNK2 and possesses a substituted aniline in a thieno[2,3-d] pyrimidine structure, is a promising starting point for the future development of novel drugs for treating or managing cancer and metabolic disease.
AB - The mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate eukaryotic initiation factor 4E (eIF4E) and play important roles in promoting tumorigenesis and metabolic disease. Thus, inhibiting these enzymes might be valuable in the treatment of such conditions. We designed and synthesized a series of 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine derivatives, and evaluated their inhibitory activity against the MNKs. We found 15 compounds that were active as MNK inhibitors and that one in particular, designated MNK-7g, which was potent against MNK1 and substantially more potent against MNK2. The compound MNK-7g did not affect other signaling pathways tested and had no adverse effects on cell viability. As expected from earlier studies, MNK-7g also inhibited cell migration. Therefore, the compound MNK-7g, which forms an ionic bond with Asp226 in MNK2 and possesses a substituted aniline in a thieno[2,3-d] pyrimidine structure, is a promising starting point for the future development of novel drugs for treating or managing cancer and metabolic disease.
KW - eIF4E inhibition
KW - Mnk
KW - Selective inhibitor
KW - Thieno[2,3-d]pyrimidine
UR - http://www.scopus.com/inward/record.url?scp=85057136408&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2018.10.070
DO - 10.1016/j.ejmech.2018.10.070
M3 - Article
C2 - 30496989
AN - SCOPUS:85057136408
SN - 0223-5234
VL - 162
SP - 735
EP - 751
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -